Trial Profile
A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- 06 Jul 2021 Status changed from active, no longer recruiting to completed.
- 17 May 2021 Planned primary completion date changed from 7 Dec 2020 to 7 Jun 2021.
- 31 Jan 2020 Planned End Date changed from 1 Oct 2023 to 7 Dec 2021.